Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs

By LabMedica International staff writers
Posted on 18 Nov 2026

Influenza and respiratory syncytial virus (RSV) often circulate during the same season and cause overlapping symptoms, making accurate differentiation important for clinical management. More...

Seasonal testing surges can also strain laboratory capacity. A newly cleared molecular test aims to streamline diagnosis by detecting and differentiating influenza A, influenza B, and RSV from anterior nasal swabs in a single run.

Molecular Designs (Birmingham, AL, USA) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its SimplicityDx Panel FluA/FluB/RSV under K262789, marking the company’s first FDA-cleared test. The assay is designed to qualitatively detect and differentiate influenza A, influenza B, and respiratory syncytial virus (RSV) RNA in anterior nasal swab specimens from patients with signs and symptoms of respiratory tract infection.

The SimplicityDx Panel FluA/FluB/RSV uses multiplex real-time reverse transcription polymerase chain reaction (RT-PCR) technology to detect all three respiratory viruses, along with an internal control, in a single run. Designed for use with Molecular Designs’ Simplicity Dx Extraction products, the panel features a breakaway format that allows laboratories to use only the tests needed for each run. This approach minimizes pipetting steps while supporting batch processing during periods of high testing demand.

The assay is intended to aid differential diagnosis when used alongside clinical, epidemiological, and other laboratory findings. It is available for prescription use only and is restricted to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.

“This is a defining moment for Molecular Designs. Earning FDA clearance requires rigorous manufacturing, robust quality systems and scientific discipline, and our team built all three. With respiratory season underway, we're ready to support labs with a cleared, practical way to test for flu A, flu B and RSV in a single run,” said Michael Clark, CEO of Molecular Designs.

“Our goal was never just to add another respiratory test. We set out to design one around how clinical labs actually work, with quality and efficiency as priorities from the start. Every choice, from the assay format to the run controls, came from working alongside lab teams and listening to what they need day to day,” said Dr. Greer Massey, Chief Scientific Officer of Molecular Designs.

Related Links
Molecular Designs


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.